ERBB2 and triple-negative breast carcinoma: Accounting for 15–20% of breast cancer, triple-negative breast cancer (TNBC) subtype lacks estrogen receptor, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression and has a poor prognosis1–4.